O	0	10	Prognostic
O	11	17	effect
O	18	20	of
O	21	32	circulating
O	33	44	adiponectin
O	45	47	in
O	48	49	a
O	50	60	randomized
O	61	62	2
O	63	64	x
O	65	66	2
O	67	72	trial
O	73	75	of
O	76	79	low
O	79	80	-
O	80	84	dose
B-intervention	85	94	tamoxifen
I-intervention	95	98	and
I-intervention	99	110	fenretinide
O	111	113	in
O	114	127	premenopausal
O	128	133	women
O	134	136	at
O	137	141	risk
O	142	145	for
O	146	152	breast
O	153	159	cancer
O	159	160	.

O	161	171	Adipokines
O	172	175	are
O	176	182	linked
O	183	185	to
O	186	193	obesity
O	194	197	and
O	198	205	insulin
O	206	217	sensitivity
O	218	221	and
O	222	226	have
O	227	235	recently
O	236	240	been
O	241	248	related
O	249	251	to
O	252	258	breast
O	259	265	cancer
O	266	270	risk
O	271	274	and
O	275	284	prognosis
O	284	285	.

O	286	288	We
O	289	301	investigated
O	302	305	the
O	306	318	associations
O	319	321	of
O	322	328	plasma
O	329	335	leptin
O	336	339	and
O	340	351	adiponectin
O	352	356	with
O	357	369	mammographic
O	370	377	density
O	378	381	and
O	382	389	disease
O	390	396	status
O	397	400	and
O	401	409	assessed
O	410	415	their
O	416	426	prognostic
O	427	433	effect
O	434	436	on
O	437	447	recurrence
O	447	448	-
O	448	452	free
O	453	461	survival
O	462	464	in
B-eligibility	465	478	premenopausal
I-eligibility	479	484	women
I-eligibility	485	487	at
I-eligibility	488	492	risk
I-eligibility	493	496	for
I-eligibility	497	503	breast
I-eligibility	504	510	cancer
O	510	511	.

O	512	514	We
O	515	523	measured
O	524	535	circulating
O	536	542	lipids
O	542	543	,
O	544	551	insulin
O	551	552	-
O	552	556	like
O	557	563	growth
O	564	570	factor
O	571	572	1
O	572	573	,
O	574	581	glucose
O	581	582	,
O	583	590	insulin
O	591	594	and
O	595	602	insulin
O	603	614	sensitivity
O	615	616	(
O	616	626	calculated
O	627	629	by
O	630	641	homeostasis
O	642	647	model
O	648	658	assessment
O	659	660	[
O	660	664	HOMA
O	664	665	]
O	666	671	index
O	671	672	)
O	672	673	,
O	674	680	leptin
O	680	681	,
O	682	693	adiponectin
O	693	694	,
O	695	698	and
O	699	705	leptin
O	705	706	-
O	706	708	to
O	708	709	-
O	709	720	adiponectin
O	721	726	ratio
O	727	729	in
B-total-participants	730	733	235
B-eligibility	734	747	premenopausal
I-eligibility	748	753	women
I-eligibility	754	758	with
I-eligibility	759	765	pT1mic
I-eligibility	765	766	/
I-eligibility	766	770	pT1a
I-eligibility	771	777	breast
I-eligibility	778	784	cancer
I-eligibility	785	786	(
I-eligibility	786	787	n
I-eligibility	788	789	=
I-eligibility	790	792	21
I-eligibility	792	793	)
I-eligibility	793	794	,
I-eligibility	795	810	intraepithelial
I-eligibility	811	820	neoplasia
I-eligibility	821	822	(
I-eligibility	822	823	n
I-eligibility	824	825	=
I-eligibility	826	829	160
I-eligibility	829	830	)
I-eligibility	830	831	,
I-eligibility	832	834	or
I-eligibility	835	836	5
I-eligibility	836	837	-
I-eligibility	837	841	year
I-eligibility	842	846	Gail
I-eligibility	847	851	risk
I-eligibility	852	854	of
I-eligibility	855	856	1
I-eligibility	856	857	.
I-eligibility	857	858	3
I-eligibility	858	859	%
I-eligibility	860	862	or
I-eligibility	863	870	greater
O	871	872	(
O	872	873	n
O	874	875	=
O	876	878	54
O	878	879	)
O	880	883	who
O	884	896	participated
O	897	899	in
O	900	901	a
O	902	903	2
O	904	905	Ã
O	905	906	—
O	907	908	2
O	909	914	trial
O	915	917	of
O	918	921	low
O	921	922	-
O	922	926	dose
O	927	936	tamoxifen
O	936	937	,
O	938	949	fenretinide
O	949	950	,
O	951	955	both
O	956	962	agents
O	962	963	,
O	964	966	or
B-control	967	974	placebo
O	975	979	over
O	980	981	a
O	982	983	2
O	983	984	-
O	984	988	year
O	989	995	period
O	995	996	.

O	997	999	At
O	1000	1008	baseline
O	1008	1009	,
O	1010	1021	adiponectin
O	1022	1028	levels
O	1029	1033	were
O	1034	1042	directly
O	1043	1053	associated
O	1054	1058	with
B-outcome	1059	1071	mammographic
I-outcome	1072	1079	density
I-outcome	1080	1083	and
I-outcome	1084	1087	HDL
I-outcome	1088	1099	cholesterol
O	1100	1103	and
O	1104	1114	negatively
O	1115	1125	associated
O	1126	1130	with
O	1131	1137	leptin
O	1137	1138	,
O	1139	1145	leptin
O	1145	1146	-
O	1146	1148	to
O	1148	1149	-
O	1149	1160	adiponectin
O	1161	1166	ratio
O	1166	1167	,
O	1168	1172	body
O	1173	1177	mass
O	1178	1183	index
O	1184	1185	(
O	1185	1188	BMI
O	1188	1189	)
O	1189	1190	,
O	1191	1194	and
O	1195	1199	HOMA
O	1200	1205	index
O	1205	1206	.

O	1207	1213	Median
B-outcome	1214	1225	adiponectin
I-outcome	1226	1232	levels
O	1233	1237	were
O	1238	1243	lower
O	1244	1246	in
O	1247	1255	affected
O	1256	1260	than
O	1261	1263	in
O	1264	1274	unaffected
O	1275	1280	women
O	1281	1282	(
O	1282	1283	P
O	1284	1285	=
O	1286	1287	.
O	1287	1290	006
O	1290	1291	)
O	1291	1292	.

O	1293	1298	After
O	1299	1300	a
O	1301	1307	median
O	1308	1310	of
O	1311	1312	7
O	1312	1313	.
O	1313	1314	2
O	1315	1320	years
O	1321	1324	and
O	1325	1330	total
O	1331	1333	of
O	1334	1336	57
B-outcome	1337	1343	breast
I-outcome	1344	1354	neoplastic
I-outcome	1355	1361	events
O	1361	1362	,
O	1363	1368	there
O	1369	1372	was
O	1373	1374	a
O	1375	1377	12
O	1377	1378	%
O	1379	1388	reduction
O	1389	1391	in
O	1392	1395	the
B-outcome	1396	1400	risk
I-outcome	1401	1403	of
I-outcome	1404	1410	breast
I-outcome	1411	1421	neoplastic
I-outcome	1422	1428	events
O	1429	1432	per
O	1433	1437	unit
O	1438	1446	increase
O	1447	1449	of
O	1450	1461	adiponectin
O	1462	1463	(
O	1463	1471	adjusted
O	1472	1478	hazard
O	1479	1484	ratio
O	1484	1485	,
O	1486	1487	0
O	1487	1488	.
O	1488	1490	88
O	1490	1491	;
O	1492	1494	95
O	1494	1495	%
O	1496	1498	CI
O	1498	1499	,
O	1500	1501	0
O	1501	1502	.
O	1502	1504	81
O	1505	1507	to
O	1508	1509	0
O	1509	1510	.
O	1510	1512	96
O	1512	1513	;
O	1514	1515	P
O	1516	1517	=
O	1518	1519	.
O	1519	1521	03
O	1521	1522	)
O	1522	1523	.

O	1524	1529	There
O	1530	1533	was
O	1534	1536	no
O	1537	1548	interaction
O	1549	1556	between
O	1557	1566	treatment
O	1567	1570	and
B-outcome	1571	1582	adiponectin
I-outcome	1583	1589	levels
O	1589	1590	.

O	1591	1594	Low
O	1595	1606	adiponectin
O	1607	1613	levels
O	1614	1617	are
O	1618	1628	associated
O	1629	1633	with
O	1634	1635	a
O	1636	1643	history
O	1644	1646	of
O	1647	1652	prior
O	1653	1668	intraepithelial
O	1669	1678	neoplasia
O	1679	1681	or
O	1682	1688	pT1mic
O	1688	1689	/
O	1689	1693	pT1a
O	1694	1700	breast
O	1701	1707	cancer
O	1708	1711	and
O	1712	1718	higher
O	1719	1723	risk
O	1724	1726	of
O	1727	1733	second
O	1734	1740	breast
O	1741	1751	neoplastic
O	1752	1758	events
O	1759	1761	in
O	1762	1775	premenopausal
O	1776	1781	women
O	1781	1782	.

O	1783	1786	The
O	1787	1799	associations
O	1800	1803	are
O	1804	1815	independent
O	1816	1818	of
O	1819	1822	BMI
O	1822	1823	,
O	1824	1836	mammographic
O	1837	1844	density
O	1844	1845	,
O	1846	1849	and
O	1850	1859	treatment
O	1859	1860	.

O	1861	1864	Our
O	1865	1873	findings
O	1874	1881	support
O	1882	1885	the
O	1886	1890	role
O	1891	1893	of
O	1894	1905	adiponectin
O	1906	1908	as
O	1909	1910	a
O	1911	1920	potential
O	1921	1927	target
O	1928	1931	for
O	1932	1945	premenopausal
O	1946	1952	breast
O	1953	1959	cancer
O	1960	1970	prevention
O	1971	1974	and
O	1975	1984	treatment
O	1984	1985	.
